Novartis’ battery-powered RFID trial shows good results, but cost still issue
Here’s the good news: Dutch trial of battery-powered RFID tags in standard medication blister packages, sponsored by Novartis, clearly shows the benefits the technology can have for patient compliance.
However, cost is still too high for adoption, ccording to this article posted earlier. The study included 275 patients, 600 packs of Novartis’s hypertension medication Diovan and 23 pharmacies in the Netherlands, seeking to establish if RFID can be used as a way to check if medication has been taken correctly.